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INTRODUCTION  
 
 INTRODUCTION 
 
 
Spinal cord injury (SCI) is a traumatic insult to the spinal cord that can result in 
alterations of normal motor, sensory, and autonomic function. It is one of the most 
catastrophic injuries because of its multi-system involvement. Patients with chronic 
SCI experience musculoskeletal effects of non-weight bearing throughout their lives. 
Osteoporosis is one of the complications of spinal cord injury. Osteoporosis is defined 
as a disease characterized by low bone mass and micro-architectural deterioration of 
bone tissue leading to enhanced bone fragility and a consequent increase in fracture 
risk(1-3) . Osteoporosis is now widely recognized as a public health problem since this 
disease, which increases bone fragility and thereby the risk of fractures, is associated 
with high mortality, morbidity and medical expenses throughout the world (1). 
Osteoporosis has been shown to have a prevalence of 70-80% in paraplegics in studies 
world wide(4), though its prevalence in traumatic spinal cord injury(SCI) in Indian 
patients has not been studied.  The decline in bone density has been detected as early as 6 
weeks post SCI and has been shown to steadily progress over the next 12-16 weeks 
before stabilizing. It is a major cause of skeletal fragility and fractures in these patients. 
The complications of fracture and their treatment cause considerable financial and social 
burden.  
 
(DEXA) Dual Energy X-ray Absorptiometry, to determine bone density is the gold 
standard in diagnosing osteoporosis. DEXA is, by far, the most widely used technique for 
bone measurements since it is considered to be cheap, accessible, easy to use, and able to 
provide an accurate estimation of bone mineral density in adults(5). 
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DXA uses two x-ray beams with differing energy levels, which are aimed at the patient's 
bones. When soft tissue absorption is subtracted out, the BMD can be determined from 
the absorption of each beam by bone. However, the radiation dose is approximately 
1/10th that of a standard chest X-ray.  DEXA provides a means to assess bone density 
and predict fracture risk in chronic SCI patients and can help in planning preventive 
measures and rehabilitation.  
Among the antiresorptive drugs, the predictive value of preclinical studies has been 
particularly well documented with the bisphosphonates(1). Bisphosphonates are stable 
analogs of pyrophosphates, chelating agents originally used by industry to prevent 
calcium carbonate precipitation in plumbing(6). Owing to their chemical composition, 
bisphosphonates have a high binding affinity with the bone. They are primary agents in 
the current pharmacological arsenal against osteoclast mediated bone loss due to post 
menopausal osteoporosis, Paget`s disease of bone, malignancies with metastatis to bone, 
multiple myeloma or hypercalcemia of malignancy. In addition to currently approved 
uses, bisphosphonates are commonly prescribed for prevention and treatment of a variety 
of other skeletal conditions such as low bone density and osteogenesis imperfecta. 
Several types of bisphosphonates are being used at present. 
Etidronate, Clondronate, Tiludronate, Pamidronate and Alendronate have been 
administered to individuals following acute and chronic spinal cord injury, in order to 
prevent bone loss. Varying results have been obtained with different bisphosphonates. 
Although the exact mechanism of the bisphosphonate-mediated osteoclast inhibition has 
not been completely elucidated, there is evidence that these substances could block 
dissolution of hydroxyapatite, inhibit differentiation of bone marrow precursors into 
osteoclasts,  inhibit osteoclast function by interfering with the mevalonate pathway of 
cholesterol biosynthesis, and induce apoptosis of osteoclasts (6).  
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 Zoledronic acid (1-hydroxy-2-imidazole-1-yl-1-phosphono-ethyl phosphonic acid), is a 
newer and more potent bisphosphonate, belonging to a new class of highly potent 
nitrogen containing bisphosphonates.   
 
(Figure 1)  Chemical structure of Zoledronic acid 
 
                                
 
 
It has been approved by the US FDA for use in hypercalcemia of malignancies and for 
treatment of postmenopausal osteoporosis. When given every year by intravenous 
infusion, the drug increases bone mineral density and reduces fracture risk in women with 
postmenopausal osteoporosis. It also reduces subsequent fractures in patients who have 
had an osteoporosis-related fracture, and increases survival in those who have sustained a 
low impact hip fracture.  In postmenopausal women, zoledronic acid produces an effect 
on bone turnover and bone density as great as those achieved with daily oral 
administration of other bisphosphonates, with proven efficacy against fractures with only 
an annual infusion. 
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  It is also used to prevent skeletal fractures in patients with cancers, such as multiple 
myeloma and prostate cancer.  Zoledronate has been approved as a once yearly 4 mg 
infusion for treatment of osteoporosis and it has shown significant benefits versus 
placebo with a reduced number of vertebral fractures and improved markers of bone 
density.  
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Comprehensive care and early rehabilitation has improved the quality of life of people    
following spinal cord injury. However osteoporosis among this group of individuals often 
predisposes them to the risk of secondary fractures and related complications. These are 
the cause of considerable financial and social burden. 
The sites and severity of skeletal bone loss can now be more accurately determined with 
use of densitometry. Bone loss has been reported to occur in the lower extremities mostly 
and DEXA scan provides a means to predict fracture risk in chronic SCI patients. This 
can help in planning fracture preventive measures during their rehabilitation. 
 Although various groups of bisphosphonates have been studied in the past for 
osteoporosis treatment and prophylaxis among SCI patients,  the results have shown only 
a modest potential benefit and the compliance poor for the forms requiring regular oral 
intake.  Zoledronic acid, a newer and more potent bisphosphonate with potential for 
single dose yearly intravenous infusion has been shown to be beneficial in osteoporosis in 
postmenopausal women and in liver transplant patients. However its benefit in 
osteoporotic chronic spinal cord injured patients needs to be studied.  If found beneficial 
it has the potential to ensure better compliance and fracture prophylaxis in our subset of 
chronic spinal cord injured patients due to the advantage of yearly dose administration.  
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Introduction 
 
Osteoporosis is a disease that occurs commonly in the rehabilitation patient population in 
its primary and secondary forms(7). Osteoporosis is a disease of the skeletal system 
characterized by low bone mass and deterioration of bone tissue leading to an increased 
risk of bone fractures (1, 2, 8). Osteoporosis due to immobilization is an important and 
increasingly prevalent clinical condition in the aged and disabled populations(9). Persons 
with traumatic spinal cord injury (SCI) undergo transition immediately from a normal 
ambulatory lifestyle to a state of markedly impaired mobility(8). The osteoporosis that 
accompanies SCI predisposes to fracture after minor trauma.  Bone mineral loss occurs 
throughout the entire skeleton, except the skull(10). Most bone loss occurs rapidly and 
below the pelvis. Homeostasis is reached by 16 months at two thirds of original bone 
mass, near fracture threshold(10). 
Conceptual Definition of Osteoporosis 
 Various definitions of osteoporosis have been offered to describe the outcome of events 
(fragility fractures), the process giving rise to porous bones, or the resultant diminution in 
bone mass. The following definition is now generally accepted ‘a disease characterized 
by low bone mass and micro-architectural deterioration of bone tissue, leading to 
enhanced bone fragility and a consequent increase in fracture risk’(1, 3) 
The  World  Health   Organization   (WHO)  defines   osteoporosis as  a  spinal  or hip 
bone mineral density (BMD) of 2.5 standard  deviations  or  more  below  the  mean for  
healthy,  young persons  (t-score of −2.5 or below) as measured by dual energy x-ray 
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absorptiometry (DEXA). Osteopenia  is defned as a spinal or hip BMD between 1 and 
2.5 standard deviations below the mean (11).  
Thus, the decrease in bone mass with changes in micro-architecture and consequent 
increased fragility represents the disease, whereas low-energy fractures represent a 
complication of the disease that will occur when the force applied to a bone, such as that 
resulting from falling, exceeds its load-bearing capacity(1). Thus, the osteporotic fracture 
depends upon several internal and external factors that are not directly related to the 
osteoporotic process. 
CLASSIFICATION OF OSTEOPOROSIS(7) 
Osteoporosis can be classified according to localization in the skeleton and according to 
etiology. Localized osteoporosis affects part of the skeleton; generalized osteoporosis 
affects, to a greater or lesser extent, different parts of the whole skeleton. Both types of 
osteoporosis can further be classified into primary and secondary osteoporosis.       
 
A.   Primary osteoporosis: basic etiology unknown, no associated disease 
1. Postmenopausal osteoporosis: elderly women 
2. Senile osteoporosis: elderly men 
   B.   Secondary osteoporosis: secondary to inherited or acquired abnormalities/diseases            
or to physiologic aberrations 
1. Hyper parathyroidism 
2. Cushing’s disease 
3. Multiple myeloma 
4. Hyperthyroidism (endogenous and iatrogenic) 
5. Idiopathic hypercalciuria 
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a. Due to renal calcium leak 
b. Due to renal phosphate leak 
6. Malabsorption (including partial gastrectomy) 
7. 25 – OH vitamin D deficiency 
a. Due to chronic liver disease 
b. Due to chronic anticonvulsant therapy (phenytoin, barbiturates) 
               8.  1, 25(OH) 2   vitamin D deficiency due to lack of renal synthesis 
a.   Due to chronic renal failure 
9. Adult hypophosphatasia   
10. Osteogenesis imperfecta tarda 
11.  Male hypogonadism (Klinefelter’s syndrome) 
12.  Female hypogonadism  (Turner’s syndrome) 
13.  Conditions consistent with hypoestrogenism secondary to anorexia and/or 
exercise 
a. Anorexia nervosa 
b. Exercise-induced amenorrhoea 
14. Conditions associated with disuse 
a. Paraplegia/hemiplegia 
b. Immobilization 
c.  Prolonged bed rest  
15. Alcoholism 
16. Diabetes mellitus  
17. Rheumatoid arthritis 
18. Chronic obstructive pulmonary disease 
19.  Systemic mastocytosis 
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20.  Conditions associated with the use of medications 
a. Corticosteroids         b.  Heparin  
c.  Anticonvulsants    d. Excess thyroid hormone 
              21.  Malignancy 
ETIOLOGY AND RISK FACTORS FOR OSTEOPOROSIS 
Risk of developing an osteoporosis related fracture is dependent on an individual`s peak 
bone mass and strength of bone achieved in one’s lifetime and the subsequent rate of 
bone loss.  Multiple etiologic factors may act independently or in combination in an 
individual patient to produce diminished bone mass. 
RISK FACTORS FOR OSTEOPOROTIC FRACTURES(7) 
Personal history of low-impact fracture 
Current low bone mineral density 
History of fracture in a first-degree relative 
Caucasian race 
Advanced age 
Female sex 
Dementia 
Recurrent falls 
Inadequate physical activity 
Poor health/frailty 
Current smoker 
Low body weight 
Estrogen deficiency 
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Corticosteroid use 
Testosterone deficiency 
Vitamin D deficiency 
Low life time calcium intake 
Alcoholism  
Impaired eye sight despite correction 
 
PATHOGENESIS(12) 
The pathogenesis of osteoporosis is complex. In childhood and adolescent period, rate of 
bone formation exceeds resorption, resulting in continued skeletal growth and denser, 
longer and heavier bones. This process slows down in adulthood, and peak bone mass is 
attained at about 30 years of age. After this, resorption begins to exceed formation. 
Normal bone loss averages 0.7 per cent per year. It gets accelerated at the time of 
menopause to 2-5 percent per year, which may continue for up to 10 years. Since 
cancellous bone is metabolically much more active than cortical bone, in periods of 
accelerated bone loss cancellous bone loss is 3-fold greater. Osteoporotic fractures 
therefore commonly occur in vertebrae. Peak bone mass is primarily determined by genes 
but may be modified to a considerable extent by factors such as physical activity, 
calcium, vitamin D nutrition, smoking, alcohol, concurrent illness and medications – 
glucocorticoids and antiepileptics. The level of peak bone mass achieved at puberty is a 
major determinant of bone mass in later life and hence an important factor in the ultimate 
development of osteoporosis. 
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Cellular abnormalities 
 
Conclusive evidence of cellular abnormalities contributing to the pathogenesis of 
osteoporosis is lacking.  It may be that failure of osteoblast (the cell responsible for bone 
formation), due to either decreased cell number or decreased cell activity, may 
accompany advancing age but is not specific for osteoporosis(7). 
DIAGNOSIS OF OSTEOPOROSIS 
 
The first clinical indication of osteoporosis, either primary or secondary, will usually be a 
fracture.  An absolute diagnosis of osteoporosis is usually made when an atraumatic 
fracture occurs in the presence of low bone mass (most typically of the spine, femur, 
and/or distal radius). However it is obviously of value from the standpoint of patient 
management to evaluate the patient at risk for fracture before a fracture occurs, as well as 
to determine the cause of the fracture in patients in whom a fracture has occurred.  
Because the amount of bone mass present is the principal determinant of fracture, a non-
invasive technique for quantifying bone mass would consequently be of value not only in 
the diagnosis of osteoporosis, but also in following a response to therapy. 
 
Methods for measuring bone mass 
             Bone mass measurements and biochemical markers of bone turnover are key methods to  
 
diagnose osteoporosis, predict future fracture, and monitor therapeutic regimens. 
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Biochemical markers of bone turnover 
 
    Markers for bone formation: 
    Serum 
    i. Osteocalcin  
    ii Bone-specific alkaline phosphatase. 
 
   Markers for bone resorption: 
   Plasma 
    i.  Tartrate-resistant acid phosphatase. 
    ii. Free pyridinoline and deoxypyridinoline and Type I collagen N and C-     
         telopeptides breakdown products. 
  Urine 
   i. Urinary pyridinoline and deoxypyridinoline (collagen cross links) and type I  
        collagen N and C-telopeptides breakdown products. 
  ii. Fasting urinary calcium and hydroxyproline.       
  iii. Urinary hydroxylysine glycosides. 
 
Roberts et al (13) demonstrated a dramatic rise in bone resorption markers, beginning 
within the first week of injury and peaking around weeks 10–16. Depending on the 
resorption marker examined, the peak was as high as 10 times the upper limit of normal. 
Values had not returned to baseline at 6 months, indicating ongoing loss of bone. 
Contrasting with the large rise in resorption markers, the change in markers of bone 
formation was modest and barely exceeded the reference range. 
12 
 Quantitating bone mass 
 
Most commonly used techniques 
 
 1. Single- and dual- photon absorptiometry (SPA and DPA respectively) 
 2. Quantitated computed Tomography. (QCT) 
 3. Single or dual-energy x-ray absorptiometry. (DXA) 
 4. Peripheral quantitated computed tomography. (pQCT) 
 
Attenuation or absorption of ionizing radiation by bone is the basic principle used in the 
majority of the noninvasive techniques (with the exception of ultrasound). A generally 
linear relationship exists between bone mass and radiation attenuation: the greater the 
amount of bone present, the greater the attenuation of ionizing radiation, and 
subsequently the less radiation quantitated in a detector(7).  
DXA is the clinical ‘‘gold standard’’ for diagnosing osteoporosis(14). DXA allows the 
measurement of bone mineral density in the axial and peripheral skeleton. Bone density 
measurements can be obtained within 30 seconds to 2 minutes with a radiation exposure 
of approximately 10 m rad (one-sixth the exposure of a chest x-ray) with 99% precision 
and approximately 97% accuracy(7). However the DEXA technology for diagnosing 
osteoporosis by measuring bone density became available in India only in 1997(12). 
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 (Figure 2) DEXA scan of left hip  (Report from Department of Endocrinology, CMC, 
Vellore) 
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(Figure 3) DEXA scan of left forearm (Report from Department of Endocrinology, 
CMC, Vellore) 
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 Interpretation of BMD analysis report
 
 
The measurements, which are carried out to three decimal places, are given in grams per 
square centimeter.  They are used to determine the T score and the Z score. The T score 
assesses the risk of fracture.  It compares the subject's BMD with the predicted mean peak 
BMD (in an average 30 year old of the same sex) and expresses the difference in standard 
deviation (SD). In other words, the T score shows how the subject’s BMD compares with 
the ideal level. A patient who’s BMD is 1 SD below that of an average 30-year-old has a T 
score of –1. The Z score determines whether the subject's bone loss is out of proportion with 
what is expected.  It compares the subject with the mean for age matched, sex-matched, and 
ethnic-matched controls and expresses the difference in SD. Thus, a 70-year-old woman 
with a Z score of –1 is 1 SD below the BMD of the average 70-year-old woman, but her T 
score is –3 because she is 3 SD below the BMD of the average 30-year-old woman. The T 
score is useful in assessing a patient's risk of fracture and deciding whether to recommend 
pharmacological therapy. In general, almost all patients whose BMD is in the osteoporotic 
range should be considered for such therapy. Many patients with values in the osteopenic 
range, particularly those in the lower end of the range or with several risk factors for 
fracture, should also be considered for pharmacological therapy. 
In a meta-analysis of how well measures of bone mineral density predict occurrence of 
osteoporotic fractures, Marshal et al concluded that bone mineral density can identify 
people who are at increased risk of developing a fracture, but it cannot with any certainty 
identify individuals who will develop a future fracture(15).  It was also found that most 
measuring sites (proximal radius, distal radius, hip lumbar spine, calcaneus, and all sites) 
had virtually the same predictive ability for a decrease of 1 SD in bone density. There were 
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two exceptions to this general observation. Measurement at the spine seemed to have a 
better predictive ability for spine fractures (relative risk 2.3 (95% confidence interval 1.9 to 
2.8)), while measurement at the hip was better for predicting hip fractures [relative risk 2.6 
(2.0 to 3.5)](15).  
 
VITAMIN D 
VITAMIN D is essential for maintaining calcium and phosphorus homeostasis, and 
optimizing bone health(16). It is widespread in nature and photosynthesized in most 
plants and animals exposed to sunlight(17). Its major role in vertebrate animals and 
humans is to increase the absorption of calcium and phosphate for the mineralization of 
the skeleton(18).  
Inadequate intake of calcium and vitamin D leads to reduced calcium absorption, 
increased serum parathyroid hormone concentrations, and bone loss (19). Dawson-
Hughes et al (19) in their study concluded that calcium and vitamin D supplementation 
leads to a moderate reduction in bone loss and may substantially reduce the risk of 
nonvertebral fractures among men and women 65 years of age or older who live in the 
community. Bischoff-Ferrari et al (20) in their meta-analysis concluded that oral vitamin 
D supplementation in the range of 700 to 800 IU/d should reduce the risk of hip or any 
non-vertebral fracture by approximately 25%. The role of additional calcium 
supplementation together with 700 to 800 IU/d vitamin D could not be clearly defined, 
but dietary calcium intakes of more than 700 mg/d may be necessary for nonvertebral 
fracture prevention(20). In a meta-analysis of randomized controlled trials, Bischoff-
Ferrari(20) described 2 physiological explanations for the beneficial effect of vitamin D 
on fracture risk in older persons. First, the well-described decrease in bone loss in older 
persons (19); and second, vitamin D appears to have a beneficial effect on muscle 
17 
strength, reduction in fall (21) and balance(22) mediated through highly specific 
receptors in muscle tissue. 
 
Physiology of vitamin D and bone mineralization 
Vitamin D3, or cholecalciferol, is synthesized in the skin(18). Its precursor, 7-
dehydrocholesterol, is converted by the UV light of the sun (UVB 290–315 nm) into 
previtamin D3, which is slowly isomerized to vitamin D3(18). Vitamin D binding protein 
(DBP) binds vitamin D and its metabolites and transports them in the bloodstream. Some 
nutrients also contain vitamin D3, e.g., fatty fish, eggs, and dairy products. Vitamin D2, 
or ergocalciferol, originates from irradiation of ergosterol, a major plant sterol, and has 
been added to dairy products and multivitamin preparations. Vitamin D2 is also 
transported in the circulation by DBP, and its metabolism is similar to that of vitamin 
D3(18). Vitamin D is hydroxylated in the liver into 25-hydroxy vitamin D [25(OH) D], 
which is the major circulating metabolite. Further hydroxylation into 1, 25-dihydroxy 
vitamin D [1, 25-(OH)2 D] occurs primarily in the kidney. The hydroxylation in the 
kidney is stimulated by PTH and suppressed by phosphate. While 25(OH) D has limited 
biological activity, 1, 25-(OH)2 D is the most active metabolite stimulating the absorption 
of calcium and phosphate from the gut. The production of 1, 25-(OH)2 D is under tight 
feedback control, directly by serum calcium and phosphate and indirectly by calcium via 
a decrease of serum PTH. 
The free serum 1, 25-(OH)2 D concentration is very low, as it is more than 99% bound to 
DBP and albumin. The active metabolite 1, 25-(OH)2 D acts through the vitamin D 
receptor (VDR), a specific nuclear receptor, related to the T4 and steroid hormone 
receptors. The VDR is present in the intestine where 1, 25-(OH)2 D, after binding to the 
VDR, stimulates the synthesis of several proteins in the intestinal cells, which participate 
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in the transport of calcium from the intestinal lumen into the bloodstream.  The VDR is 
also present in many other organs such as bone, muscle, pancreas, and pituitary. The 
active metabolite 1, 25-(OH)2 D influences muscle function and stimulates cell 
differentiation and immunological function in general. The action of 1, 25-(OH)2 D on 
bone is not well understood. It stimulates the osteoblasts to produce osteocalcin and 
alkaline phosphatase. On the other hand, 1, 25-(OH)2 D stimulates bone resorption in 
vitro. The effects of 1,25-(OH)2D on bone mineralization appear to be indirect by 
stimulating the calcium and phosphate supply, mainly by absorption from the gut(18). 
The bone remodeling sequence by which new osteons are formed starts with osteoclasts 
resorbing existing bone. Thereafter, osteoblasts appear and construct the new un-
mineralized bone matrix, the osteoid. Subsequently, the osteoid is mineralized. The 
mineralization of the osteoid occurs in two phases. During primary mineralization, about 
half of the bone mineral accumulates within a few days, increasing the density to 1.4 g/ 
cm
3
. The secondary mineralization proceeds more slowly during 6 months or more and 
increases the density to 1.9 g/cm
3
(18). When mineralization is normal, the mineral 
content of an osteon depends on its age. Young, low-density bone is more prevalent when 
bone turnover is high. Older, completely mineralized high-density bone is associated with 
low bone turnover. 
 
Consequences of Vitamin D Deficiency - Secondary hyperparathyroidism and high 
bone turnover 
A low serum 25(OH) D concentration is the hallmark of vitamin D deficiency(18). The 
1,25-dihydroxy vitamin D assay should never be used for detecting vitamin D deficiency 
because levels will be normal or even elevated as a result of secondary 
hyperparathyroidism (23). The low serum 25(OH) D concentration leads to a decrease of 
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serum 1, 25-(OH)2 D and calcium absorption. The lower serum calcium concentration 
causes an increase of PTH secretion, which stimulates the production of 1, 25-(OH)2 D. 
By this mechanism serum 1, 25-(OH)2 D is kept at (nearly)  normal levels at the expense 
of a higher serum PTH concentration, which is referred to as “secondary 
hyperparathyroidism.” It implicates that serum PTH is relatively high for the associated 
serum calcium concentration, although it may still be within normal reference limits(18). 
 
(Figure 4) Metabolism of vitamin D and the biologic actions of 1,25-
dihydroxycholecalciferol  
 
 
Vitamin D3 supplementation causes a decrease of the serum PTH concentration, a 
decrease of bone turnover, and an increase of bone mineral density(18). Recent 
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recommendations suggest that in the absence of sun exposure, adults should ingest 1000 
IU of vitamin D3 per day. The ideal healthy blood level of 25-hydroxyvitamin D should 
be 30 to 60 ng/mL. Vitamin D intoxication occurs when 25-hydroxyvitamin D levels are 
greater than 150 ng/mL(24). 
 
Adami et al in 2008 concluded that optimal vitamin D repletion seems to be necessary to 
maximize the response to anti-resorbers in terms of both BMD changes and anti-fracture 
efficacy(25). They also found that the adjusted incidence of clinical fracture is 77% 
higher in vitamin D depleted women(25). Shinchuk(16) et al found that Vitamin D 
deficiency, osteopenia and osteoporosis are highly prevalent in both men and women 
admitted for subacute rehabilitation after an acute hospitalization. Bone remodeling 
activity was elevated with a disproportional increase in bone resorption. It was suggested 
that this, could be due to vitamin D deficiency that should be corrected before 
antiresorptive therapy is considered(16). 
 
Proposal for staging of vitamin D deficiency (18)- Lips et al 
Mild Vitamin D deficiency (Vitamin D insufficiency)   -  10-20 ng/ml 
Moderate Vitamin D deficiency                                      -    5-10 ng/ml 
Severe Vitamin D deficiency                                          -    <5    ng/ml 
 
Untreated, Vitamin D deficiency will lead to development of osteopenia and osteoporosis 
defined by World Health Organization (WHO) as bone mass 1 and 2.5 standard 
deviations (SDs) below the sex-controlled young adults, respectively(16). 
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MANAGEMENT OF OSTEOPOROSIS 
 
Because osteoporosis results in fractures due to minimal trauma, rapidly effective therapy 
is required to reduce fracture risk(26). Treatment of osteoporosis includes 
pharmacological and non-pharmacological methods. 
 
NON-PHARMACOLOGICAL TREATMENT 
The avoidance of lifestyles known to result in bone loss, including cigarette smoking, 
excessive alcohol intake, lack of exercise, and so forth, should be addressed along with 
recommendations for nutritional and pharmacologic therapy(7). Morse et al reported that 
increased alcohol consumption after SCI may exacerbate sublesional bone loss(27). 
 
Fall prevention 
A multifactorial approach that addresses vision deficits, balance and gait abnormalities, 
cognitive impairment, and dizziness is the cornerstone of fall prevention. Improving 
lighting, removing loose rugs, and adding grab bars near bathtubs, toilets, and stairways 
can enhance safety(28). 
 
NUTRITIONAL ADJUNCTS 
 
 
Calcium 
 
It is a mainstay of osteoporosis prevention and treatment. Recommended minimum 
calcium intake is 1000 to 1500 mg/day in all perimenopausal and postmenopausal women 
and for men is 800 to 1500mg.  Calcium is generally safe (in the absence of a history of 
previous kidney stones, or of idiopathic hypercalciuria), comparatively inexpensive, and 
logistically simple to ingest.  A predisposition for kidney stones and nephrolithiasis may 
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be seen.  A urinary calcium excretion of up to 250 mg per 24 hours is acceptable in 
individual without a history of kidney stones(7). 
 
Vitamin D 
400 to 800 IU per day of vitamin D is recommended. This will help to increase calcium 
absorption at the gut level, and use of active form of vitamin D analogs as calcitriol may  
result in increased risk for kidney stones or for hypercalciuria, nephrolithiasis, or even 
nephrocalcinosis(7).  
 
Protein 
 
Along with calcium and vitamin D supplementation, protein supplementation has been 
shown to favorably affect outcomes in patients who have sustained hip fractures. The 
RDA for protein is 44 g/day for women and 56 g/day for men(7). 
 
PHARMACOLOGICAL TREATMENT OF BONE MASS DEFICIENCY 
 
The treatment of osteoporosis and osteopenia is directed at preservation or improvement 
of bone mass at the specific target sites. Because bone mass is the principal, although not 
the only, determinant of fracture, such preservation or improvement of bone mass is 
associated with a reduced risk of fracture. The axial and appendicular sites exhibit 
varying proportions of cortical (compact) and trabecular (cancellous) bone. Trabecular 
bone is metabolically more active than cortical bone(7). Trabecular bone appears to be 
preferentially altered in osteoporosis and is the type of bone most affected by medications 
used in the treatment of osteoporosis. 
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A number of U.S. Food and Drug Administration (FDA) approved therapeutic agents are 
available to decrease bone resorption (anti-bone resorbers). There are also a number of 
therapeutic modalities that increase bone formation (positive bone formers)(7).  
Antiresorptive Agents 
Among the antiresorptive drugs, the predictive value of preclinical studies has been 
particularly well documented with the bisphosphonates.  
Bisphosphonates are primary agents in the current pharmacological arsenal against 
osteoclast-mediated bone loss due to osteoporosis, Paget`s disease of bone, malignancies 
metastatic to bone, multiple myeloma, and hypercalcemia of malignancy(29). 
Structurally, bisphosphonates are chemically stable derivatives of inorganic 
pyrophosphate (PPi), a naturally occurring compound in which 2 phosphate groups are 
linked by esterification(29). It is the most commonly used treatment for established 
osteoporosis, inhibits osteoclast-mediated bone resorption and reduces the risk of 
vertebral fracture. Maimoun et al cited that bisphosphonates reduce bone loss in both the 
early and chronic phases of SCI, even though the demineralization process cannot be 
stopped(30). 
The various bisphosphonates available are etidronate, tiludronate, alendronate, 
risedronate, palmidronate, zoledronate and ibandronate. Of these, once-a-week 
formulations are available for alendronate and risedronate. Ibandronate is available as 
once a month oral formulation. Newer bisphosphonates such as tiludronate, pamidronate, 
and alendronate are respectively 10, 100, and 1000 times more potent than etidronate(30). 
Oral bisphosponates have limitations related to long-term compliance, gastrointestinal 
intolerance, and poor and variable absorption from the gastrointestinal tract(31). Because  
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food  and  certain minerals  reduce the  absorption  of  bisphosphonates,  they should be 
taken at  least 30 minutes before the first food, drink (other than water), or medication of 
the day(26). Tablets should be swallowed with 6 to 8 oz of water. To reduce  the risk of 
gastroesophageal  irritation, patients  should  remain  upright  for  at  least  30 minutes 
after dosing(26). 
Intermittent intravenous administration of bisphosphonates might address some of these 
problems and has been shown to be effective in the treatment of malignant hypercalcemia 
and Paget’s disease and to reduce the rate of skeletal complications in patients with breast 
carcinoma or multiple myeloma(31). An intravenously administered bisphosphonate may 
have a potential advantage over oral preparations in that oral preparations require that the 
patient maintain upright posture, which may not be possible for weeks in SCI patients 
with osteoporois and pressure ulcers, which may prevent the patient from being seated 
upright.  
Intravenous bisphosphonates available in market are palmidronate, zoledronate and 
ibandronate. Reid et al stated that intermittent intravenous administration of the potent 
bisphosphonate - zoledronic acid results in changes  in biochemical markers of bone  
turnover  and  in bone mineral density that are similar to those observed with daily oral 
bisphosphonate therapy(31). Black et al demonstrated that during a 3-year period, an 
annual infusion of 5 mg of zoledronic acid significantly reduced the risk of fracture at all 
key osteoporotic fracture sites, including the two primary end points, vertebral and hip 
fractures(32). 
Intravenous bisphosphonates have been shown to be potent inhibitors of bone resorption 
in a wide variety of conditions associated with increased osteoclastic function.  
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Because of their multifactorial pharmacological effects on inhibition of the osteoclast, 
bisphosphonates may be hypothesized to be efficacious in reducing or preventing the 
osteoporosis associated with immobilization. Bisphosphonate therapy has also reduced 
the increased urinary calcium excretion in able-bodied individuals restricted to bed rest. 
Zoledronic acid (1-hydroxy-2-imidazole-1-yl-1-phosphono-ethyl phosphonic acid), a 
newer and more potent bisphosphonate, belongs to a new class of highly potent nitrogen 
containing bisphosphonates.  Zoledronic acid is approved by the FDA for the treatment, 
but not the prevention, of osteoporosis(33). A single administration of Zoledronic acid 
has been found to ameliorate bone loss and maintain parameters of bone strength at the 
three proximal femur sites for 6 month and at the femur intertrochanteric and shaft sites 
for 12 months(34). Because it has high potency, only small doses are required for the 
inhibition of bone resorption, and long dosing intervals may be used(31). Prolonged  
suppression  is not  the  result of  the persistence of the drug in the circulation, given that 
by 24 hours after administration, drug levels are less than 1 percent of the post 
administration peak and 40 percent of the dose has been excreted in the urine(31). The 
balance of the dose is presumably bound to bone and is slowly released back into the 
circulation, giving rise to a 167-hour terminal half-life in plasma.  
Reid et al found that Zoledronic acid was generally well  tolerated, and the rate of 
retention of subjects in the study was high(31). He also stated that the adverse events that 
were more common in women receiving zoledronic acid were those that have occurred  
previously  in  patients  receiving  intravenous aminobisphosphonates and were transient. 
In the zoledronic acid groups, most adverse events were instances of musculoskeletal 
pain, nausea, or  fever, most of which were  rated as mild(31). Infrequent doses may 
increase tolerance of these side effects. Crawford et al found that despite a total of 20 mg 
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of zoledronic acid being administered over 12 months to patients with major co-morbid 
conditions, there was no increase in adverse events other than temporary, induced 
secondary hypoparathyroidism and hypocalcemia(35). However since late 2003, an 
increasing number of reports suggest a possible association between the use of 
bisphosphonates and avascular necrosis of the jaws. The risk of ONJ associated with oral 
bisphosphonate therapy for osteoporosis seems to be low, estimated between 1 in 10,000 
and <1 in 100,000 patient-treatment years(36). The risk of ONJ in patients with cancer 
treated with high doses of intravenous bisphosphonates is clearly higher, in the range of 
1-10 per 100 patients (depending on duration of therapy). MacLean et al in his systematic 
review found multiple published cases of osteonecrosis of the jaw in patients with cancer 
who received large doses of bisphosphonates intravenously.  
Reid et al also cited that intermittent intravenous administration of the potent 
bisphosphonate zoledronic acid results in changes  in biochemical markers of bone  
turnover  and  in bone mineral density that are similar to those observed with daily oral 
bisphosphonate therapy(31). 
Estrogen 
Estrogen is also approved by the FDA for preventing osteoporotic fractures in 
postmenopausal women(33). The evidence suggests that estrogen reduces the risk for 
vertebral and hip fracture; however, the effect of estrogen on nonvertebral fracture risk is 
less clear. 
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Selective estrogen receptor modulators (SERM) 
Selective estrogen receptor modulators (SERMs) have been developed to provide 
beneficial effects similar to those obtained with estrogen, but without the adverse 
effects(7). The common SERMs used are tamoxifen, raloxifen or droloxifen. Raloxifene 
(evista), a selective estrogen receptor modulator, is approved for the  treatment of 
postmenopausal osteoporosis(11). Raloxifene has estrogen agonist activity on the bones 
and lipids, and an estrogen antagonist effect on the breast and uterus. Raloxifene is 
effective for reducing the incidence of vertebral fractures,  but effectiveness at the hip has 
not been shown.  
Raloxifene is commonly associated with increased vasomotor symptoms. Although 
raloxifene increases the risk of venous thromboembolism, it is indicated to decrease the 
risk of invasive breast cancer in postmenopausal women with osteoporosis(11). It may 
be best used in postmenopausal women with osteoporosis who are unable to tolerate 
bisphosphonates, have no vasomotor  symptoms or history of venous thromboembolism, 
and have a high breast cancer risk score(11).  
Salmon Calcitonin 
 
Both  intranasal  and  injectable  forms  of salmon  calcitonin  (Miacalcin)  are  approved 
for  the  treatment  of  postmenopausal  osteoporosis. Calcitonin  inhibits  bone  
resorption and  is  recommended  for use  in women with osteoporosis who  are  at  least  
five  years  past menopause  and  cannot  take other  agents(26).  
Adherence to osteoporosis treatment 
The term adherence comprises both compliance and persistence to treatment. 
Compliance refers to how the medication is taken or quality of intake. Persistence is 
defined as the time from initiation to discontinuation of treatment(37). In one of the  
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largest survey to date that has been carried on treatment adherence to osteoporosis 
treatment, Rossini et al(37) found that the mean discontinuation rate was 19%, over a 
mean period of follow up of 14 months. The study population consisted of 9851 
postmenopausal women who had been referred to the osteoporosis centres at least 1 year 
after having been prescribed one of the drugs registered in Italy for postmenopausal 
osteoporosis therapy at the time the study was initiated (2002). The most frequent reasons 
for discontinuation were drug related side effects, insufficient motivation to treatment, 
and apprehension regarding side effects(37). Treatment compliance is particularly poor 
for Calcium and Vitamin D and this emphasizes the need for new ways to supplement at 
least vitamin D.  
 
Anabolic agents (Positive bone formers) 
 
Parathyroid hormone 
Parathyroid hormone, or fragments of the intact peptide molecule, may be of value in 
osteoporosis when administered parenterally. Such a usage is based on a presumed 
anabolic effect of parathyroid hormone when administered as a fragment, and it may be 
of value in established osteoporosis in terms of stimulating bone formation. The FDA 
approved the use of parathyroid hormone for the treatment of osteoporosis in 2002(7). 
 
Recombinant human parathyroid hormone (Teriparatide) 
 
Teriparatide  (Forteo), is a recombinant human parathyroid hormone (rhPTH[1-34]),  
with  potent bone  anabolic  activity(11). It is approved for the treatment of 
postmenopausal women with severe bone loss, men with osteoporosis who have a high 
risk of fractures, and persons who have not improved on bisphosphonate therapy(11). In  
a dosage of 20 mcg per day given subcutaneously for up to two years, teriparatide 
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decreases vertebral and nonvertebral fractures(38). Because the long-term effects of 
teriparatide are not known, this agent is approved for a maximum of two years of use in 
patients with severe osteoporosis who are at high risk for fractures(26).  Adverse effects 
may include orthostatic hypotension, transient hypercalcemia, nausea, arthralgia, and leg 
cramps.  Increased risk of osteosarcoma is seen in rats exposed to high doses(11).  
Consequently, teriparatide is contraindicated in  patients with  risk  of  osteosarcoma,  
such  as those with Paget`s disease, previous skeletal  radiation, or unexplained 
elevation of  alkaline phosphatase level(11).  
 
Fluoride 
Fluoride as sodium salt has been introduced in the therapy of human osteoporosis without 
any well documented preclinical assessment of the relationship between bone mass and 
strength(1). Sodium fluoride must be viewed as an experimental therapy with some 
concerns regarding its overall usage in osteoporosis. 
 
Experimental therapies 
1. Anabolic Steroids 
These currently experimental agents may actually have a beneficial effect on bone mass; 
their side effects include liver toxicity, masculinisation, and an increased cholesterol 
level(7). 
2. Testosterone 
This may be of value in the treatment of osteoporosis in elderly men, particularly those 
with hypogonadism.  Prostate and cholesterol status should always be checked when 
using testosterone(7). 
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OSTEOPOROSIS IN SPINAL CORD INJURY 
 
Osteoporosis is a known consequence of spinal cord injury (SCI) and occurs in almost 
every SCI patient(39). The signiﬁcance of osteoporosis after SCI is that it results in 
skeletal fragility and an increased risk of fractures. Complications from fractures lead to 
an increase not only in the associated morbidity and mortality, but also in the health care 
costs that they generate. These fractures predispose to exuberant callus that may cause 
pressure sores or may mimic infection or thrombosis. Fractures are often complicated by 
profuse diaphoresis and an increase in spasticity(13). The porous nature of the bones 
means that surgical fixation is often difficult; conservative treatment with plaster casts 
can result in pressure sores. Vestergaard et al (40) found that low-energy fractures were 
much more prominent in patients (19.0% of all fractures) than in controls (1.4%, P < 
0.001). The fracture rate did not differ before the injury but increased after the injury to a 
constant level from the third year and forward. Fractures of the lower extremities were 
more prominent in patients than controls while fractures of the forearms and clavicles 
were absent among patients. Fractures were more frequent in female patients and in male 
patients with a family history of fracture.  
The pattern of bone loss seen in SCI patients is diﬀerent from that in osteoporosis, which 
occurs as a result of other etiologies such as endocrine diseases, nutritional disorders and 
drug-related factors(39).  
 
Mechanism of bone loss in SCI 
The effect of mechanical loading on bone tissue is an increase in bone formation on the 
periosteal bone surfaces, thus improving bone strength and reducing bone turnover and 
bone porosity(2). Consequently, mechanical loading can improve both bone size and 
shape and strengthen the bone tissue by improving tissue density.  
31 
 Unloading 
Kondo et al (41) revealed that sympathetic nervous tone is mediating unloading-induced 
bone loss via reduction in osteoblastic cell activity as well as enhancement in osteoclastic 
cell activity. SCI causes unloading and restricted movement of the lower limb joints for 
substantial periods of time, and substantial muscle atrophy has been seen in SCI patients. 
Unloading may play an important role in the development of osteoporosis after SCI(42). 
 
Neuronal changes - Denervation 
Innervation of bone is reported to have trophic effects on bone metabolism and a growing 
number of experimental and clinical studies indicate that innervation is important for 
bone remodelling(2). Similarly, SCI may lead to a signiﬁcant decrease in innervation 
density and neuropeptides in the sublesional bones, thus distorting the balance of bone 
formation and resorption. In addition to the direct role of denervation on bone 
metabolism, denervation after SCI can cause disordered vasoregulation, thus affecting 
bone remodelling. 
 
Hormonal changes 
Although upper limbs are normally loaded and innervated, bone loss also occurs in the 
upper extremities in patients with paraplegia. Therefore, systemic hormones such as PTH, 
vitamin D3, sex steroids, thyroid hormone and leptin may also be involved in bone loss 
following SCI(2). 
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Calcium balance 
In general, SCI patients showed negative calcium balance with hypercalciuria after the 
injury(43). The increased osteoclastic bone resorption is mainly responsible for 
hypercalciuria following SCI(2). Exercises and ambulation signiﬁcantly decrease the 
hypercalciuria and modify the calcium balance in a positive direction(44), indicating that 
immobilization may be an important factor resulting in this negative calcium balance. 
 
PTH and vitamin D 
 Secretion of PTH and the increase in circulating 1,25(OH)2  vitamin D are subjected to 
control by negative feedback mechanisms related to serum calcium level(2). In addition, 
hypercalcaemia after injury may lead to this PTH–vitamin D axis suppression in the acute 
phase of SCI. PTH suppression in SCI patients is also associated with the degree of 
neurological impairment. In a cross-sectional study, Mechanick et al (45) investigated 
serum PTH and 1,25 (OH)2 vitamin D levels in SCI patients, who were tested at a mean 
of 76·5 days post-injury, and found that patients with complete SCI, when compared to 
those with incomplete injury, had a greater suppression of the PTH–vitamin D axis. 
However, a reversal in parathyroid activity from 1 to 9 years after injury has been noted. 
The parathyroid gland is stimulated to the point where PTH levels are above the reference 
range. Secondary hyperparathyroidism has always been thought to accelerate the 
development of SCI-induced osteoporosis(2). Bauman et al (46) showed mild secondary 
hyperparathyroidism in a subgroup of subjects with chronic SCI. 
 
Effects on gonadal function 
Sex steroids play a pivotal role in regulating bone remodelling.  Thus, a decrease in the 
circulating concentrations of these hormones increases osteoclast precursor formation in 
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the bone marrow and thus increases the number of mature osteoclasts in cancellous 
bone(47). The inhibitory effect of SCI on the synthesis and secretion of sex steroids 
therefore contributes to the pathogenesis of SCI-induced osteoporosis. Maimoun et al 
(48)  reported recently that total testosterone and the free androgen index were 
signiﬁcantly lower in SCI patients than in able-bodied controls. 
  
A neurological lesion, (such as SCI) with subsequent immobilization, leads to a dramatic 
reduction in muscle contraction and a redistribution of the gravitational forces applied to 
the skeleton, to the detriment of the bone segments that normally support body 
weight(30). Garland et al found significant differences (p less than 0.0001) in bone mass 
mineral between groups at the arms, pelvis, legs, distal femur, and proximal tibia, with no 
differences in bone mass of the head or trunk(10). Wilmet et al (49) observed a rapid 
decrease of BMC in the paralyzed areas, of approximately 4%/month during the first year 
in areas rich in trabecular bone and of approximately 2%/month in areas containing 
mainly compact bone. No significant change in BMC was observed in the supra-lesional 
areas. These data confirm the rapid loss of bone in the paralyzed areas of paraplegic 
patients, which occurs independently of the presence of spontaneous muscle activity or of 
passive verticalisation(49). Demirel et al (50)found a significant difference in BMD 
between upper and lower extremities of paraplegics. BMD of upper and lower extremities 
were similar in tetraplegics. The BMD values were significantly different when the upper 
extremity scores of paraplegics and tetraplegics were compared but BMD scores of the 
lower extremities were similar in the two groups(10, 50). The decrease in BMD was less 
in the spastic patients when compared to the flaccid group. There was a positive 
correlation between time from injury and the degree of BMD deficit in the paralyzed 
areas(50).  
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To limit the bone loss resulting from neurological lesions, a logical approach would be to 
develop rehabilitation techniques that mechanically re-stimulate the bone segments to 
return, as much as possible, to the pre-lesional physiological and biomechanical 
conditions(30). 
 
 MANAGEMENT OF OSTEOPOROSIS IN SPINAL CORD INJURY 
Morse et al (27) cited that, although admission for osteoporotic fractures accounted for only 
2.6% of the admissions, these hospitalizations resulted in longer lengths of stay than other 
admissions, and individuals also required increased levels of assistance for transfers and 
self-care during immobilization of a fractured limb. Hence prevention of fractures would 
therefore decrease health care costs and promote independence in this population. 
 
NON-PHARMACOLOGICAL MANAGEMENT 
 
Prevention of falls 
Morse et al (27) also found that the most common cause of fracture in chronic spinal cord 
injury was falls, which may be difficult to prevent. However, based on record review, 
20% of the fractures resulting in hospitalization were due to transfer and wheelchair 
ambulation technique. It may be possible to reduce fracture risk by improving counseling 
and educating patients regarding limb protection during various self-care activities and 
reinforce the importance of adequate doorway width for wheelchair clearance(27). 
 
Standing-up and orthotically aided walking 
The study by De Bruin et al (51) indicates that early mobilization led to no or 
insignificant loss of trabecular bone, whereas the immobilized individuals showed a 
marked decrease when monitored for 25 weeks. In addition, the recent prospective study 
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by Alekna et al (52) found that standing, particularly after 2 years, gave significantly 
higher BMD in legs, pelvis and the total body. 
 
Physical exercise 
The quality of evidence available for evaluation is poor (53). Miyahara et al (54) found 
that the earlier the athlete started sports after injury, the higher the BMD of the legs, body 
trunk and the entire body. Further, a longer period of athletic career after restarting was 
significantly related to higher leg BMD.  
 
Functional electrical stimulation 
Functional electrical stimulation is a method of exercise that has been employed in the 
SCI population that has demonstrated some success in improving muscle, with less 
conclusive evidence that it has a positive effect on bone(14). Be Dell et al (55) 
demonstrated that there was no significant increase in bone density in the hip parameters 
of chronic SCI patients after functional electrical stimulation induced lower extremity 
cycling, though a positive trend was observed in the lumbar spine. Giangregorio et al (14) 
demonstrated that nine months of thrice weekly FES cycle ergometry failed to increase 
BMD at the femoral neck, distal femur, and proximal tibia in individuals with complete 
SCI. 
 
Low-intensity pulsed ultrasound 
Naruse et al (56) demonstrated that low-intensity, pulsed ultrasound, which has been 
clinically used to accelerate the healing processes of fractured bone, induces a direct 
anabolic reaction of osteogenic cells, leading to bone matrix formation. Warden et al (57) 
applied speciﬁc US at the calcaneum for 6 weeks in young subjects with 1–6-month 
histories of complete SCI. The results showed that low-intensity pulsed US were unable 
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to protect against SCI-induced calcaneal bone demineralization. Further investigations 
are needed. 
 
PHARMACOLOGICAL MANAGEMENT  
The physiopathological data have shown that bone demineralization in patients with SCI 
can be principally attributed to an alteration of the bone remodeling process that 
dramatically favors an increase in bone resorption. Drug treatment thus mostly consists of 
substances that inhibit osteoclast cell activity(30).  
 
Calcitonin 
Calcitonin is a potent inhibitor of bone resorption. Transcutaneous injection or intranasal 
intake of salmon calcitonin has been reported to limit immobilization hypercalcemia and 
hypercalciuria, to reduce osteoclast activity, and to preserve trabecular bone volume. 
However, the optimal dosage and long-term eﬀectiveness of calcitonin treatment remain 
unclear(30). 
 
Bisphosphonates in osteoporosis after spinal cord injury 
Various bisphosphonates such as alendronate, palmidronate, etidronate have been tried in 
patients with osteopororis after spinal cord injury.  
Chappard et al (58) observed an insignificant decrease of bone volume in the placebo 
group and the patients who received 200 mg/day of tiludronate. In patients receiving 400 
mg/day, a slight increase was noted. Eroded surfaces increased in all groups. The number 
of osteoclasts (identified histochemically by TRAP staining) was found to have increased 
in the placebo group but decreased in groups receiving tiludronate. Chappard et al 
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concluded that tiludronate appeared to be effective in reducing bone resorption without 
impairing bone formation in a manner that preserved bone mass and bone cell coupling. 
Pearson et al (59) found that there was significant interaction between etidronate 
treatment and ambulatory status over time with respect to bone density of the patients 
after SCI (p = .0003). They found that the patients who became ambulatory and received 
etidronate treatment had a preservation of bone density as compared to all other patients 
who showed a loss of bone density over time. The loss of bone density occurred in the leg 
bones, not the spine. They also concluded that cyclical etidronate is a feasible treatment 
and may prevent osteoporosis associated with SCI in patients who eventually walk. 
Nance et al (60) found that after acute SCI, patients treated with intravenous pamidronate 
had significantly less bone density loss compared with those who did not receive 
pamidronate ( p<.02). Also, ambulatory subjects had significantly less bone density loss 
over the study period (p<.05) than nonambulatory subjects. Nance et al concluded that 
intravenous pamidronate treatment and ambulatory ability in the first 6 months after an 
acute spinal cord injury prevents bone density loss. 
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AIMS AND OBJECTIVES 
 
 
 
       To study the effect of a single dose of intravenous zoledronic acid in subjects with chronic 
spinal cord injury on the bone mineral density in the forearm and hip after 1 year of 
intervention.  
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 MATERIALS AND METHODS 
 
 
STUDY DESIGN: Randomised double blind placebo control study.  
The study was approved by the institutional review board and signed informed consent 
was obtained from each subject prior to enrollment.  Patients attending the Physical 
Medicine and Rehabilitation out patient department, those admitted in the wards and 
those attending the yearly spinal cord injury follow up Mela were recruited based on 
inclusion and exclusion criteria after preliminary screening. Those who fulfilled the 
inclusion criteria, underwent a baseline DEXA scan to detect the prevalence of 
osteoporosis. In those detected to have osteoporosis of the hip or femur neck, the 
following investigations were done which included 
1)  Serum sodium  
2)  Serum potassium 
3) Serum calcium  
4) Serum phosphorus 
5) Serum creatinine  
6) Serum urea 
7) 25 OH Vitamin D 
8) X-ray of the pelvis with both hip joints 
 
The patients were then enrolled, after proper informed consent into a randomized, double 
blinded trial to receive either a single dose intravenous infusion of Zoledronic acid (study 
group) or  normal saline (placebo group). These patients were reassessed with DEXA 
bone densitometry after 1 year to compare and analyse the difference in bone density at 
the femoral neck and forearm.  
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INCLUSION CRITERIA: 
1) Patients who are more than 12 months post traumatic spinal cord injury. 
2) Age group 18- 60 years. 
 
EXCLUSION CRITERIA: 
1) Patients with non traumatic spinal cord lesions. 
2) Patients with renal failure. 
3) Heterotrophic ossification involving both hips. 
4) Patients with recent onset grade 4 pressure sores that may hinder DEXA bone 
densitometry study. 
5) Patients already on other medication or treatment regimens for osteoporosis treatment 
or prophylaxis. 
6) Postmenopausal women. 
Sample size 
 
A descriptive study with randomised, double blinded analysis was planned. Using the 
formula:  
                       n =  (Z a x Z 1-b ) x 2 p x q _ 
                                        d2 
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Here,  (Z a x Z 1-b) is   a   constant coefficient with  ‘a’ being the type 1 error 
and ‘1-b ’ being the power of the study. For a study with 80% power and a type 1 error 
of less than 5%. The coefficient value usually is around 10.4. 
n is the sample size of the study. 
p is the prevalance of osteoporosis in the study population and q signifies the non 
osteoporotic  normal population calculated as ‘1-p’ . 
d is the approximate percentage difference between the study and control arms.  
Comparing with other similar studies worldwide the prevalence of osteoporosis was 
hypothesized to be 80% in SCI. The approximate percentage difference between the 
study and control arms from zoledronic acid studies done in transplant patients 
worldwide was around 50%. 
Using the above formula, the sample size in each arm was estimated to be 15, so a total of 
30 and considering a 25% loss to follow up due to various reasons a sample size of 40 
was arrived upon in consultation with the statisticians. 
Randomization 
The patients were allocated into treatment and control arms by stratified, blocked, random 
method. The randomization code was prepared by the statistician and handed over to the in-
charge of manufacturing unit in Pharmacy who then distributed the vials (drug/saline) for 
infusion. 
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Intervention 
The patients in the treatment arm received injection zoledronic acid 4 mg in 100 ml normal 
saline, while the control arm received plain normal saline, intravenously over 20 minutes. 
These solutions were prepared in the Pharmacy of the Christian Medical College Hospital, 
Vellore.  Both the physician and the patient were blinded to the treatment allocation. The 
patients were observed for one day post injection for possible complications from the 
medication.  
Measurements 
Total of 73 subjects with spinal cord injury were screened for osteporosis at the hip using 
DEXA scan- [Delphi W (S/N 70471) version 11.2]. These individuals were recruited 
during the period from February to July 2008, from the yearly spinal cord injury follow 
up Mela 2008 and from among those individuals who attended the out patient services of 
the department of Physical Medicine and Rehabilitation.  Out of these 11 people were 
found to have normal bone mineral density at the hip, 31 osteopenic and another 31 
osteoporotic. Twenty eight (28) osteoporotic subjects with chronic SCI (more than 12 
months) who gave their informed consent were enrolled into a double-blind, placebo-
controlled study for determining the effect of bisphosphonate administration on loss of 
bone following chronic spinal cord injury.  The other 3 patients who did not give consent 
were excluded.  
Repeat DEXA scan [Discovery W (S/N 70471) version 12.7.3.1] was done 1 year post 
study drug infusion.  
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(Figure 5)  Photograph of the DEXA scan table 
 
DEXA scan measurement procedures 
Patients with Spinal Cord Injury, who fulfilled the inclusion criteria were subjected for the 
first DEXA scan. Standard technical parameters were followed according to DEXA 
scanning user guide instructions.  A hip positioner or foot restraint was used to maintain 
the leg rotated inwards by 25 degrees and foot was firmly strapped to the device.  Cross 
hair of the laser light was centered 3 inches below the level of the Greater trochanter & 
slightly medial to the shaft of femur.  The regions to be scanned (hip and forearm) were 
graphically displayed, and the operator adjusted the final cut lines for each division. 
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Quality control was done using phantoms to ensure reproducibility and accuracy of BMD 
measurement. Measurements were made at base line and at 1 year follow up. 
(Figure 6)  Position for DEXA forearm and femur 
 
 
 
 
 
Statistical analysis 
 
 
Statistical analysis was performed using SPSS (statistical package for social sciences) 
version 16 with the help of a Clinical Epidemiologist. Two-tailed paired t tests (P<0.05) 
were performed on BMD data for the placebo and zoledronic acid group, to test for 
significant differences within group before and after intervention. Since the sample size 
was small and some of the data showed a skewed distribution (did not follow a normal 
distribution curve), it was decided in consultation with the statistician, to use non-
parametric tests for analysis.  
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RESULTS 
 
 
PATIENT DEMOGRAPHY 
 
 
Age distribution 
 
In the placebo group the mean age of all the patients was 38.35 years (range from 24 to 
58 years). In the zoledronic acid group the mean age of all the patients was 37.91 years 
(range from 30 to 56 years).  There was no statistically significant difference between the 
two groups with respect to age, (p value = 0.777). 
 
Figure 7 
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 Gender distribution 
 
 
In the placebo group there were 14 males and no females. In the zoledronic acid group 
there were 9 males and 3 females. 
 
Figure 8 
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Figure 9 
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Neurological level  
 
 
In the placebo group there were 2 patients with a high lesion (cervical and upper thoracic) 
and 12 patients with a low level lesion (lower thoracic and lumbar). 
In the zoledronic acid group there were 3 patients with a high lesion and 9 patients with a 
low level lesion. There was no statistically significant difference between the two groups 
with respect to the level of lesion. (p value 0.498) 
 
Figure 10 
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Duration of injury 
 
 
In the placebo group the mean duration of injury was 10.92 years (range from 3 to 25 
years). 
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In the zoledronic acid group the mean duration of injury was 13.33 years (range from 2 to 
22 years). 
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There was no statistically significant difference between the two groups with respect to 
the duration of injury (p value 0.279).   
Figure 12 
Figure 11 
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Vocation 
The total number of patients in the placebo group and zoledronic acid group were divided 
into two depending upon the nature of their vocation (outdoor and indoor).  In the 
placebo group 8 patients were involved in indoor vocation while 6 patients were involved 
in outdoor vocation.  In the zoledronic acid group 7 patients were involved in indoor 
vocation while 5 patients were involved in outdoor vocation.  
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There was no statistically significant difference between the two groups with respect to 
the nature of vocation (p value 0.952). 
Figure 13 
Figure 14 
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 Sun exposure 
 
The total number of patients in the placebo group and zoledronic acid group were divided 
into two depending upon the amount of sun exposure per week as those receiving less 
than 1 hour of sun exposure per week and those receiving more than 1 hour of sun 
exposure per week. There was no statistically significant difference between the two 
groups with respect to amount of sun exposure (p value 0.952) 
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Figure 15 
Figure 16 
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Vitamin D  
 
There was no statistically significant difference between the zoledronic acid and the 
placebo group with respect to the level of vitamin D (p value 0.757). 
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Mobility 
 
In the placebo group, out of 14, half the patients were ambulant and half non ambulant. In 
the zoledronic acid group 8 out of 12 patients were ambulant while 4 were non ambulant. 
There was no statistically significant difference between the two groups with respect to 
the mobility (p value 0.400) 
Figure 17 
Figure 18 
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Adverse events 
 
Five out of the 28 subjects had flu-like syndromes, including bone pain, fever, fatigue, 
and rigors. One participant reported of myalgia for almost 2-3 months following the 
infusion. Another individual had post injection conjunctival redness.  It was later found 
on opening the randomization code that all the subjects with adverse effects were in the 
zoledronic acid group. 
 
Two of the participants did not follow up after 1 year for the repeat DEXA scan. One of 
them developed fracture of the left tibia while attempting to transfer to a chair about 10 
months after the study drug infusion. On opening the randomization code, it was found 
that this subject had received placebo. 
 
Figure 19 
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The mean and standard deviation values of the BMD at the hip, femur neck, forearm and 
distal radius, prior to and after intervention for both drug and placebo group are 
mentioned in table 1.  
 
 
 
 
 
Non parametric test - Wilcoxon signed ranks test was used to look for statistically 
significant difference between bone mineral density at total hip, femoral neck, total 
forearm and distal third of radius, post intervention in both the zoledronic acid group and  
the placebo group. 
           
 
BMD 
Total hip 
 
 
BMD 
Femoral Neck 
 
 
BMD 
Total forearm 
 
 
BMD 
Distal third of radius 
 
 
 
 
Pre 
  
 
 
    Post 
 
       
 
     Pre 
 
 
 
      Post 
 
     Pre 
 
     Post 
 
      Pre 
 
     Post 
  
Mean 
 
 
SD 
 
Mean 
 
 
SD 
 
Mean 
 
 
SD 
 
Mean 
 
 
SD 
 
Mean 
 
 
SD 
 
Mean 
 
 
SD 
 
Mean 
 
 
SD 
 
Mean 
 
 
SD     
 
Zoledronic 
acid group 
 
0.583 
 
 
0.066 
 
 
0.563 
 
 
0.079 
 
 
0.576 
 
 
0.064 
 
 
0.552 
 
 
0.074 
 
 
0.588 
 
 
0.065 
 
 
0.623 
 
 
0.080 
 
 
0.717 
 
 
0.066 
 
 
0.760 
 
 
0.072 
 
P value                    0.082                 * 0.044                  * 0.002                  * 0.004 
 
Placebo 
group 
 
0.607 
 
0.073 
 
0.491 
 
0.169 
 
0.548 
 
0.111 
 
0.480 
 
0.163 
 
0.589 
 
0.036 
 
0.612 
 
0.0
36 
 
0.713 
 
0.031 
 
0.747 
 
0.028 
P value                  * 0.017                   *0.002                   *0.004                   *0.004 
Table 1 
54 
                    
 
 
Fig 20 illustrates the pre and post intervention BMD values of total hip in the zoledronic acid group. 
 
 
There was a statistically significant reduction in bone mineral density at the total hip in 
the placebo group ( p = 0.017) while the reduction in bone mineral density in the subjects 
who received zoledronic acid (p = 0.082)was not statistically significant. 
 
Figure 20 
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Figure 21 illustrates the pre and post intervention BMD value of total hip in the placebo group. 
 
 
  
In one subject the post intervention DEXA scan could not be measured at the hip  
 
due to technical difficulties. The updated version of the software could not detect total 
 
 hip value, as an osteotomy had been performed at the hip.   
   
 
 
There was a statistically significant drop in the bone mineral density post intervention at 
the femoral neck in both the zoledronic acid group (p value = 0.044) and the placebo 
group (p value = 0.002). The drop in the bone mineral density, post intervention was 
greater in the placebo group as compared to the zoledronic acid group. 
 
Figure 21 
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Figure 22 illustrates the BMD of femoral neck in zoledronic acid group, pre and post intervention. 
             
Figure 23 represents the pre and post intervention BMD of femoral neck in the placebo group. 
Figure 22 
Figure 23 
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Bone mineral density scores of total forearm showed a statistically significant 
improvement post intervention in both the zoledronic acid (p value = 0.002) and placebo 
group (p value = 0.004). The improvement in the bone mineral density post intervention 
was more in the zoledronic acid group as compared to the placebo group. 
 
           
 
 
 
 
Figure 24 illustrates the BMD of total forearm, pre and post intervention in the zoledronic acid group. 
 
 
 
 
 
 
 
  
Figure 24 
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Figure 25 represents the BMD of total forearm, pre and post intervention in the placebo group. 
 
          
 
 
 
There was statistically significant improvement in the bone mineral density at distal 
radius in the zoledronic acid group (p value = 0.004) as well as the placebo group (p 
value = 0.004). The improvement was similar in both the groups. 
            
Figure 25 
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       Figure 26 BMD of distal third of radius pre and post intervention in the zoledronic acid group 
 
                    
 
. Figure 27 represents the BMD of distal third of radius pre and post intervention in the placebo group.   
Figure 26 
Figure 27 
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Mann Whitney test was applied to look for statistically significant difference in 
percentage change in bone mineral density at the hip, femur neck or distal radius between 
the zoledronic acid and the placebo group.  
 
Percentage change in bone mineral density was calculated using the formula – 
 
(BMD post intervention – Baseline BMD)* 100 
                         Baseline BMD 
 
 
 
There was no statistically significant difference in percentage change in bone mineral 
density at the hip (p value = 0.227), femur neck (p value = 0.471) or distal radius (p value 
= 0.758) between the zoledronic acid and the placebo group. 
 
 
 
 
Correlation between BMD and Vitamin D value 
 
The Spearman`s correlation coefficient comparing the percentage change in BMD of 
femur neck and and Vitamin D level in the 12 patients of the zoledronic acid group was 
0.039 (p=0.905) showing there was no correlation between these two.    
The Spearman`s correlation coefficient comparing the percentage change in BMD of 
femur neck and and Vitamin D level in the 14 patients of the placebo group was 0.037 
(p=0.899) showing there was no correlation between these two.    
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Figure 28 & 29 represent percentage change in BMD at femur neck in relation to the serum vitamin D 
level in the zoledronic acid group and placebo group respectively.  
Figure 28 
Figure 29 
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 Figure 30 & 31 represent percentage change in BMD at distal radius in relation to the serum vitamin D 
level in the zoledronic acid group and placebo group respectively.  
 
 
 
 
 
Figure 30 
Figure 31 
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The Spearman`s correlation coefficient comparing the percentage change in BMD of 
distal radius and Vitamin D level in the 12 patients of the zoledronic acid group was -
0.046 (p=0.888) showing there was no correlation between these two. 
The Spearman`s correlation coefficient comparing the percentage change in BMD of 
distal radius and Vitamin D level in the 14 patients of the placebo group was 0.029 
(p=0.923) showing there was no correlation between these two.    
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DISCUSSION 
 
DISCUSSION 
 
 
Bone is constantly remodeling, with an increase in bone resorption, typically followed 
within 30 to 45 days by the process of bone formation. With normal bone remodeling, 
there is no net change in the amount of bone mass present(7) in young adults. In most 
forms of osteoporosis, however, a perturbation of bone remodeling occurs. Bone 
resorption increases over the normal levels, and bone formation does not compensate for 
this increase, with a net loss of bone mass overall(7). In any condition that causes 
immobilization, loss of bone occurs and is correlated to the severity of unloading. 
Osteoporosis is a well recognized complication of SCI(13). Nearly all patients who 
sustain SCI will experience a signiﬁcant loss of BMD in their paralyzed extremities, 
resulting in a greatly increased risk for fracture(61). The incidence of lower extremity 
fractures in SCI patients was found to be ranging from 1 to 34% (40, 62). With each 0.1 
g/cm
2 
and each unit of t-value decrement of BMD at the femoral neck the risk of fracture 
increases by a factor of 2.2 and 2.8 times, respectively(4). 
In an attempt to prevent osteoporosis, a common complication in the SCI population, we 
used a single IV dose of zoledronic acid and compared it with placebo. 
DEXA is the most widely used technique to examine BMD because of its high accuracy 
and low radiation exposure(63). In our study 73 patients with SCI, underwent BMD 
scanning to diagnose osteoporosis. 
We identified certain physical barriers during this study (which were also described by 
Morse et al (64) in their study), which interfered with dual energy x-ray absorptiometry 
in individuals with spinal cord injury. These barriers represent a significant limitation to 
widespread DXA scanning in the disabled, particularly, in the SCI population. The scan 
table height was too great for standard independent transfers from a wheelchair. To 
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overcome the physical barrier of the tabletop height, 3 persons were required to assist 
with lifting subjects from the wheelchair to the scanner table. The average positioning 
and scan time for subjects with more complete and higher SCI levels was between 30 to 
45 minutes. This is considerably longer in duration than the average positioning and scan 
time (20 minutes) for DXA exams in the general population. This extra time was needed 
to assist patients during transfer to the tabletop and during repositioning of paralyzed 
limbs for the scanning of the various skeletal sites. Positioning the lower limbs for 
scanning was especially difficult in patients who had spasticity.  
 Of the 73 subjects who underwent DEXA scan, 31 (42.5%) subjects met the WHO 
criteria for osteoporosis at the hip (T score < minus 2.5). Another 31 subjects (42.5%) 
were osteopenic (T score <minus 1), and 11 subjects (15%) had normal BMD. This was 
slightly different from the findings of Lazo et al (4) who, in their study  found that (61%)  
were osteoporotic, (19.5%) osteopenic, and another (19.5%) were normal.  
The two study groups (zoledronic acid group and the control group) had similar baseline 
characteristics with respect to age, duration of injury, neurological level, vitamin D 
status, mobility, sun exposure and nature of vocation.  However, there was difference 
with respect to gender distribution. In this study there were 23 males and 3 females. All 
the 3 female participants happened to be in the zoledronic acid group. This male: female 
ratio suggests that males are affected more commonly than females in traumatic SCI in 
India. Similar gender distribution with men suffering traumatic spinal cord injury more 
commonly than women in the ratio of 4:1 was also described by others(7). As the 
numbers of female participants in the study population is very small, it is not possible to 
evaluate the difference in osteoporosis with regard to gender in the spinal cord injured 
population.  
Regarding age, Morse et al described that in contrast to the general population where 
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greater age is a risk factor for osteoporosis, age was not a predictor of fracture 
hospitalization(27).  
Of the 31 subjects with osteoporosis, 26 were included in the randomized controlled 
study, 3 refused consent and 2 were lost to follow up. Of the 26 subjects, 12 were found 
to have vitamin D deficiency (<10 ng/ml) while another 12 had vitamin D insufficiency 
(10-20 ng/ml).  Only 2 out of the 26 had normal vitamin D levels. None of these patients 
were on calcium or Vitamin D supplements. Morse et al (27) in their study on 
osteoporotic fractures and hospitalization risk in chronic SCI, found that no one was 
taking any medications for osteoporosis, such as anti-resorptives (bisphosphonates) or 
calcium/vitamin D, prior to admission. Moreover, no one left the hospital with a 
prescription for osteoporotic medications, and osteoporosis was not added to anyone’s 
problem list on discharge (27). Bischoff-Ferrari et al (20) in their meta-analysis of 
randomized control trials on fracture prevention with vitamin D supplementation or 
without calcium supplementation, reported that for trials using 700 to 800 IU/d oral 
vitamin D, there is a significant (26%) reduction in risk of sustaining a hip fracture and a 
significant 23% reduction in risk of sustaining any non vertebral fracture. In contrast, 400 
IU/d vitamin D did not appreciably reduce hip or non-vertebral fractures in older persons 
supplemented with calcium. Some studies show a positive effect of calcium and vitamin 
D supplementation on BMD in peri and postmenopausal women(65). However there are 
no data available on the protective efficacy of calcium and vitamin D supplementation in 
SCI subjects. The risk of hypercalciuria and renal stone disease in SCI subjects may have 
precluded use of calcium and vitamin D.  
In our study we did not find any correlation between the vitamin D levels and the 
percentage change in BMD at the hip or forearm after intervention. In spite of the lack of 
correlation between vitamin D status and the percent improvement in BMD at the hip and 
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forearm in this small series of patients, it is probably necessary to optimize vitamin D 
status before giving zoledronic acid, as this may afford additional protection. In our series 
of SCI subjects, all except 2 were vitamin D insufficient or deficient according to Lips 
criteria. This may have obscured a potential beneficial effect of optimal vitamin D levels 
(>20 ng/ml). In other words, if we had a large number of patients with optimal vitamin D 
levels, the BMD changes in response to zoledronate may have been better.  
 
Out of the 28 patients who were initially recruited into the study, one patient had a 
history of hairline fracture of upper tibia, secondary to fall from a chair during transfer. 
There were no other patients among the 28 who reported any fracture. This patient had a 
T12 complete paraplegia. Garland et al.(66) reported motor complete injury to increase 
both knee osteoporosis and lower extremity fracture rates when compared to motor 
incomplete injury. Morse et al (27) in their study had  findings in agreement with this and 
stated that individuals with motor complete injury are at greatest risk for fracture 
hospitalization. The site of fracture sustained by the patient, is one of the most common 
sites of osteoporotic fracture seen in SCI patients. Morse et al (27) reported that the most 
common fracture requiring hospitalization in chronic SCI was a tibia/fibula fracture 
(47.5%), followed by the distal femoral metaphysis (20%) and then the proximal femur 
(15%). Humerus (5%), metatarsal (5%), and phalanx (7.5%) fractures were less common. 
Fall from a wheelchair was the most common cause (51%), followed by falls during 
transfers 14%), and lower extremity getting caught on a doorframe while operating a 
wheelchair (6%). In our study too the fracture was sustained secondary to a fall during 
transfer. Frisbie et al reported that the rate of femoral fractures in male SCI patients is 
greater than that of the general population by factors of 104 and 24 at ages 50 and 70, 
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respectively(62). The lower relative risk in older age group subjects is due to increased 
femoral fracture rates at age 70 in the general population. 
In our study, we have evaluated the effect of a single dose of zoledronic acid on the bone 
mineral density at the hip and forearm in chronic SCI subjects. Our study revealed that 
osteoporosis due to the paralysis and immobility was observed in 42.5% of the chronic 
SCI individuals and osteopenia in 42.5%. Only 15% of these subjects had normal BMD.  
There was a statistically significant reduction in the BMD of total hip at 1 year after 
placebo, whereas the patients who received zoledronic acid did not show such a 
statistically significant reduction in total hip BMD. 
Considering the femoral neck, even though there was a statistically significant reduction 
in placebo as well as the zoledronic acid group, the magnitude of decrease in BMD was 
greater in placebo recipients suggesting a protective effect of zoledronic acid. This 
observation suggests that administration of zoledronic acid in patients with SCI, can 
reduce the extent of osteoporosis. 
Interestingly the BMD in the forearm demonstrated a statistically significant rise in both 
the placebo as well as the zoledronic acid group. This could be attributed to the fact that 
individuals with paraplegia use their upper limbs for mobility with aids like crutches or 
wheelchair, which exposes the upper limbs to increased mechanical load. The effect of 
mechanical loading is highlighted by studies which show that BMD of the dominant hand 
are 5% higher than the non-dominant side(67). However Sergi et al found no significant 
differences in BMD between the dominant and non-dominant upper limbs in men or 
women(68), using peripheral quantitative CT. It is not clear whether this is because they 
used a different technique for BMD measurement. 
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LIMITATIONS  
OF THE 
 STUDY 
LIMITATIONS OF THE STUDY 
 
• The limitations of this study include a relatively small sample size in each arm of 
the study. A larger number of patients would have increased the reliability of the 
conclusions. 
• The patients were followed up only once after one year of drug infusion. Continuing 
follow up yearly after measuring BMD may give us a true picture of the extent of the 
ongoing bone loss and whether zoledronic acid prevents fractures in these patients.  
• The study was not powered to determine fracture prevention.  
• Vitamin D was not administered to any of the participants in the study. However, 
no correlation between percentage change in BMD and vitamin D was observed 
in this study.  
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CONCLUSION 
 
CONCLUSION 
 
 
• The prevalence of osteoporosis and osteopenia in our group of SCI subjects was 
high at 42.5 % each. 
• The reduction in bone mineral density at the hip and femoral neck was partially 
mitigated in subjects who received a single dose of zoledronic acid. 
• The bone mineral density in the forearm showed a statistically significant rise in 
both the placebo and zoledronic acid group, presumably related to greater 
mechanical loading of upper limbs in paraplegic subjects. 
• A longer duration study with a larger number of subjects is needed to determine if 
the observed beneficial effect of zoledronic acid on BMD will translate into 
reduced fracture rates in subjects with chronic SCI. 
• The majority of subjects with chronic SCI (92%) are vitamin D deficient or 
insufficient. The optimum dose of calcium and vitamin D supplementation for 
these subjects and the potential effect of such supplementation need to be 
determined. These doses will probably be lower than what is recommended for 
postmenopausal osteoporosis as chronic SCI subjects are at risk for hypercalciuria 
and renal stone disease.  
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RECOMMENDATION  
FOR  FUTURE  STUDY 
     
      
 
 
 
 
 
 
  
 
 
RECOMMENDATION FOR FUTURE STUDY 
 
 
The short comings of this study could be over come by designing a future study to test 
the effect of a single 4-mg dose of zoledronic acid, 
• given after correction of vitamin D deficiency, 
•  with vitamin D and calcium supplementation,  
• with an adequate sample size, and  
• study powered to measure fracture risk in Indian population with spinal cord 
injury, would provide data to help in management of osteoporosis in SCI.  
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1. Patient information sheet 
2. Informed consent document 
3. Data sheet 
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1.  PATIENT INFORATION SHEET 
 
 
You are being requested to participate in a study to see if a drug called Zoledronic acid 
can help you with increasing the strength of the bones in your paralyzed limbs. The 
advantage of Zoledronic acid is that it needs to be taken in an injectable form only once 
yearly and it has been proven to be effective in strengthening bones in patients with weak  
(osteoporotic) bones due to other conditions like in post menopausal women and in 
cancer patients with weak bones. However, effect of Zoledronate has not been studied in 
patients with post injury paralysis. There are other drugs like Alendronate, which can 
help you do the same but the disadvantage is that, it has to be taken once a week on 
empty stomach and can cause gastritis. We hope to include about 40 people from this 
hospital for this study. 
 
Does Zoledronic acid have side effects? 
Zoledronic acid has been used by many people world wide to help improve the strength 
of bones in patients with weak (osteoporotic) bones due to other conditions like in post 
menopausal women and in cancer patients with weak bones. The majority of the patients 
have not had side effects. However, some people have experienced side effects like fever, 
chills and bone and muscle aches. In most of these cases it was mild and temporary and 
did not require any specific treatment. Some people also had fall in blood calcium and 
phosphate levels but these did not require treatment. Occasionally nausea, vomiting and 
swelling or redness at the site of injection may occur. Some people have had rash, itching 
and chest pain. Some isolated cases have had redness of eyes (conjunctivitis) and fall in 
blood Magnesium levels. There also have been some reports of impaired kidney function. 
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If you take part what will you have to do? 
If you agree to take part in this study, you will be given either Zoledronic acid mixed 
with normal saline as an infusion or plain normal saline without Zoledronic acid in it. 
This is done so that we can be sure that any improvement in the strength of your bones as 
will be measured by DEXA scan will be actually due to Zoledronic acid and not due to 
chance (coincidence). Neither you nor your doctor will have any choice in whether you 
get Zoledronic acid or plain saline as this will be decided by a computer program; this is 
like tossing a coin and you have an equal chance of getting either Zoledronic acid or 
saline. Also neither you nor your doctor will know which one you have had till the study 
is over. 
 
Any other medications, which you are regularly on, and activities, which you routinely do 
like walking with callipers or using wheelchair/tricycle will be continued during the 
study. You are expected to come for review exactly 1 year after you receive the injection. 
If at any time you experience any problems you will be expected to report this to the 
doctor.  
 
Can you withdraw from the study once it starts? 
Your participation in this study is entirely voluntary and you are free to decide to 
withdraw permission to participate in this study. If you do so, this will not this will not 
affect your usual treatment at this hospital in any way.  
 
Will you have to pay for the study medications or the tests, which you need to undergo as 
part of the study? 
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The blood tests, x-ray examination, DEXA scan as well as Zoledronic acid or plain 
saline, which you will receive, will be given to you free of cost.  
 
What happens after the study is over? 
You may or may not benefit from the study drug, which you are given. Once the study is 
over and Zoledronic acid is found to be beneficial, those study subjects who had received 
saline will be given Zoledronic acid free of cost. 
 
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not be 
identified by name in any publication or presentation of results. However, your medical 
notes may be reviewed by people associated with the study, without any additional 
permission, should you decide to participate in this study. 
 
If you have any further questions please ask Dr Shiela Mary Varghese 
Telephone no – 0416 2282158 / 9994453379. 
Email – drshielavarghese@yahoo.co.in 
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2.   FORMAL INFORMED CONSENT DOCUMENT 
 
  
Study title: A randomised double blinded case control study of effect of Zoledronic acid 
on bone mineral density in osteoporotic chronic spinal cord injured patients.  
 Study Number: 
Participant`s name: 
Date of birth/Age (in years): 
I  _____________________________________________________ son/daughter of 
_____________________________ 
Confirm that I have read the information sheet provided to me regarding this study and 
have had the opportunity to ask questions. 
I understand that my participation in the study is voluntary and that I am free to withdraw 
at any time, without giving any reason and without my medical care or legal rights being 
affected. 
I also understand that neither I, nor my doctors will have any choice or knowledge of 
whether I will get the original drug (Zoledronic acid) or the identical looking placebo. 
I also understand that during the study the drug or the placebo will be provided free, but 
after this, if the drug (Zoledronic acid) is found useful and prescribed, I may have to pay 
for it. 
I understand that the study staff and the institutional ethics committee members will not 
need my permission to look at my health records even if I withdraw from the trial. I agree 
to this access. 
However, I understand that my identity will not be revealed in any information released 
to third parties or published. 
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I agree not to restrict the use of any data or results that arise from this study provided, 
such a use is only for scientific purpose(s). 
I voluntarily agree to take part in this study. 
 
 
Signature (or thumb impression) of the subject/legally acceptable representative): 
Date: 
Signatory`s name: 
Signature of the Investigator: 
Date: 
Study Investigator`s name: 
Signature of the witness: 
Date: 
Name of the witness: 
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1 132195C 1 1 2 1 1 2 2 8.50 72 1 0.503 0.52 0.54 0.70 0.46 0.46 0.56 0.76 
2 129772B 2 1 2 1 2 1 1 8.00 61 1 0.505 0.43 0.43 0.56 0.41 0.36 0.44 0.59 
3 019254C 1 1 2 1 1 2 2 8.70 75 1 0.5 0.61 0.59 0.72 0.46 0.42 0.62 0.78 
4 887076A 1 2 2 2 2 1 2 9.00 117 1 0.54 0.57 0.55 0.69 0.53 0.53 0.60 0.77 
5 123960B 1 2 2 1 2 2 2 8.20 76 1 0.48 0.58 0.60 0.74 0.44 0.51 0.59 0.72 
6 043825B 1 2 2 1 2 1 2 8.50 70 2 0.51 0.61 0.64 0.77 0.51 0.55 0.71 0.84 
7 426173B 1 2 1 1 2 1 1 8.60 70 1 0.48 0.50 0.62 0.77 0.47 0.48 0.65 0.84 
8 905578A 1 2 2 2 2 1 2 8.40 102 1 0.57 0.61 0.63 0.76 0.54 0.58 0.70 0.81 
9 167131C 1 1 2 2 1 2 2 9.00 80 1 0.49 0.48 0.65 0.76 0.45 0.48 0.65 0.77 
10 584157B 1 1 2 1 1 1 1 8.90 67 1 0.56 0.65 0.61 0.71 0.57 0.64 0.65 0.77 
11 058499B 1 1 2 1 2 2 2 8.80 61 1 0.61 0.62 0.64 0.73 0.60 0.62 0.66 0.73 
12 365246C 1 2 1 2 1 1 2 9.00 59 1 0.57 0.71 0.56 0.71 0.54 0.41 0.55 0.73 
13 200480C 1 1 2 1 1 1 1 8.10 98 1 0.53 0.77 0.62 0.73 0.00 0.00 0.64 0.75 
14 416843A 1 2 2 1 2 1 1 8.30 84 1 0.91 0.63 0.65 0.73 0.77 0.73 0.68 0.74 
15 818969B 2 1 1 1 1 2 1 9.00 50 1 0.64 0.64 0.56 0.66 0.60 0.62 0.59 0.73 
16 109186C 2 1 1 1 1 1 1 8.60 71 1 0.63 0.61 0.53 0.68 0.67 0.63 0.55 0.73 
17 849484B 1 1 2 2 1 2 2 8.60 62 1 0.68 0.65 0.66 0.81 0.62 0.59 0.70 0.85 
18 378227C 1 1 2 2 1 2 2 9.40 84 2 0.55 0.57 0.62 0.74 0.56 0.59 0.65 0.73 
19 230271B 1 2 2 2 2 2 1 9.20 112 1 0.46 0.59 0.55 0.64 0.43 0.48 0.58 0.68 
20 636654A 1 2 2 2 2 1 2 9.10 80 2 0.57 0.54 0.55 0.68 0.54 0.58 0.57 0.75 
21 850466A 1 2 2 2 2 2 2 8.10 66 2 0.53 0.62 0.57 0.69 0.51 0.51 0.61 0.74 
22 673129A 1 2 2 2 2 1 2 8.70 99 2 0.52 0.55 0.57 0.73 0.49 0.52 0.58 0.72 
23 960428C 1 1 2 2 1 2 2 9.50 103 2 0.64 0.58 0.62 0.74 0.61 0.59 0.68 0.76 
24 972226C 1 1 1 1 1 1 1 9.10 55 1 0.55 0.59 0.56 0.68 0.54 0.50 0.61 0.75 
25 175492D 1 1 2 1 1 1 1 9.50 88 1 0.59 0.66 0.59 0.74 0.57 0.69 0.60 0.79 
27 230543D 1 1 2 1 1 1 1 9.3 77 2 0.47 0.6 0.59 0.703 0.46 0.57 0.62 0.75 
 
